http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 07:00:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html <p>Ashlins Pharmaceuticals announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950).</p> <p>Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.</p> <p>Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.</p> <p>Interferon alpha-2b is a recombinant human type I interferon used as the active substance http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html Tue, 21 Jul 2026 07:00:24 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html <p>Ashlins Pharmaceuticals announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950).</p> <p>Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.</p> <p>Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.</p> <p>Interferon alpha-2b is a recombinant human type I interferon used as the active substance http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html Tue, 21 Jul 2026 07:00:24 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html <p>Ashlins Pharmaceuticals announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950).</p> <p>Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.</p> <p>Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.</p> <p>Interferon alpha-2b is a recombinant human type I interferon used as the active substance http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html Tue, 21 Jul 2026 07:00:24 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html <p>Ashlins Pharmaceuticals announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950).</p> <p>Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.</p> <p>Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.</p> <p>Interferon alpha-2b is a recombinant human type I interferon used as the active substance http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html Tue, 21 Jul 2026 07:00:24 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html <p>Ashlins Pharmaceuticals announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950).</p> <p>Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.</p> <p>Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.</p> <p>Interferon alpha-2b is a recombinant human type I interferon used as the active substance http://www.streetinsider.com/Corporate+News/Ashlins%2C+Lee%27s+Pharm+strike+license+deal+worth+up+to+%2431M/26791989.html Tue, 21 Jul 2026 07:00:24 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Press+Releases/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html <p> Lee’s is eligible to receive up to $31 million in upfront and milestone payments. </p> <p> NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience. </p><p> Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize<b> </b>certain<b> </b>drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the http://www.streetinsider.com/Business+Wire/Ashlins+Pharmaceuticals+and+Lee%27s+Pharm+Announce+Exclusive+License+and+Supply+Agreement+Valued+at+Up+to+%2431+Million/26791975.html Tue, 21 Jul 2026 07:00:00 -0400 0950 A.50216985 L1PA O.17572560 O.73447718 http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/Press+Releases/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560 http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html <div class="xn-content"> <ul type="disc"><li>Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential</li><li>Synergistic and complementary to Lee's Pharm's existing products pipeline, and</li><li>Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB</li></ul><p><span class="legendSpanClass"><location value="LC/hk" idsrc="xmltag.org" >HONG KONG</location></span>, <span class="legendSpanClass"><chron>Dec. 9, 2025</chron></span> /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> incorporated and wholly owned subsidiary of <span value="HongKong:0950" idsrc="xmltag.org" >Lee's Pharmaceutical Holdings Limited</span> (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from <span value="ACORN:4012892386" idsrc="xmltag.org" >Alexza Pharmaceuticals, Inc.</span> ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of http://www.streetinsider.com/PRNewswire/Lee%27s+Pharmaceutical+Holdings+Limited+Acquires+Staccato%C2%AE+One+Breath+Technology%C2%AE+Platform+and+Assets%2C+Driving+Pipeline+Expansion+and+Advancing+Global+Partnership+with+UCB+Through+Acquired+Rights/25715131.html Tue, 09 Dec 2025 08:00:00 -0400 0950 A.40128923 O.05077400 O.17572560